TrialSpark Stock

trialspark.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $246.91MM

TrialSpark is a technology company focused on accelerating the pace of clinical trials to bridge the gap between medical research and patients who need treatment.

Register To Buy and Sell Shares

For more details on financing and valuation for TrialSpark, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access TrialSpark’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like TrialSpark.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Kit Dobyns
Benjamine Liu Ph.D
Co-Founder & Chief Executive Officer
Linhao Zhang

Frequently Asked Questions About TrialSpark’s Stock

Can you buy TrialSpark’s stock?
TrialSpark is not publicly traded on NYSE or NASDAQ in the U.S. To buy TrialSpark’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell TrialSpark’s stock?
Yes, you can sell stock of a private company like TrialSpark. Forge can help you sell your TrialSpark stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is TrialSpark’s stock price?
TrialSpark is a privately held company and therefore does not have a public stock price. However, you may access TrialSpark’s private market stock price with Forge Data.
What is TrialSpark’s stock ticker symbol?
TrialSpark does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

23andMe and TrialSpark Announce Joint Clinical Trial Offering and Request For Proposals
NEW YORK, Sept. 26, 2019 /PRNewswire/ -- 23andMe, the leading consumer genetics company, and TrialSpark, a technology company enabling physician practices to...
23andMe's new deal with TrialSpark looks to clinical trial recruitment
The partners announced that they are putting out a request for clinical trial proposals in the areas of dermatology, gastroenterology, pulmonology, endocrinology, ophthalmology, inflammatory diseases, neurology, women’s health and rare diseases.
Updated on: Apr 19, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.